Lisata And GATC Health Partner To Revolutionize Drug Development With AI-Powered Optimization

Lisata Therapeutics, a clinical-stage pharmaceutical company focused on advanced solid tumours and serious diseases, has entered a strategic collaboration with GATC Health, a tech-bio company utilizing AI to enhance drug discovery. The partnership will combine Lisata’s expertise in drug development with GATC’s AI-driven Multiomics Advanced Technology™ (MAT) platform to accelerate and optimize drug research, improving the chances of success while reducing risks and costs.

David J. Mazzo, PhD, President and Chief Executive Officer of Lisata, said in a statement, “Lisata is delighted by the prospects of this agreement and is honored to be chosen as a strategic partner by GATC. It is noteworthy that GATC has been selected as the exclusive AI partner of Lloyd’s of London’s syndicate, Medical & Commercial International, and their marketing partner, Acrisure, to support the underwriting of the first insurance-backed financial program to fund clinical trials. 

He further added, “Additionally, we are excited by the plans for GATC to engage Lisata as a collaborator in the advancement of their own drug development candidates. By combining our expertise with GATC and their cutting-edge AI technology, we are ensuring that Lisata’s and GATC’s development programs have the highest probability of success, allowing us the ability to conduct the most time- and capital-efficient studies to accelerate products to market for the benefit of patients, the medical community, and our shareholders.”

As an initial step, GATC’s MAT AI platform will analyze Lisata’s investigational drug, certepetide, to identify optimal development pathways and assess safety, efficacy, and trial outcomes. This AI-powered analysis will help Lisata refine its Phase 3 trials for certepetide in metastatic pancreatic ductal adenocarcinoma (mPDAC) and explore additional indications with strong therapeutic potential. The collaboration will also extend to identifying combination therapies involving certepetide and exploring non-oncology applications.

“GATC’s validated technology inverts predicted clinical trial failures and provides an unbiased analysis of investigational new drugs, such as Lisata’s certepetide. This enables a derisked and optimized development roadmap that can include additional indications and new intellectual property related to the drug candidate. We are also pleased to collaborate with Lisata to leverage their expertise for GATC’s pipeline of assets,” stated Jayson Uffens, Chief Technology Officer at GATC.

Beyond certepetide, Lisata may also serve as an operational partner for GATC’s own drug candidates, which span areas like addiction, PTSD, obesity, and cognitive decline. By utilizing AI, the companies aim to revolutionize traditional drug development, significantly cutting time, cost, and failure rates. This strategic collaboration is expected to create more efficient research processes, ensuring a higher success rate for drug candidates and improved capital allocation in the biopharmaceutical sector.